Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Sanofi-Aventis pays big in new deal with Regeneron

Executive Summary

Sanofi-Aventis and Regeneron are collaborating again, this time for the discovery, development, and sale of therapeutic antibodies using Regeneron's VelociSuite platform of technologies in a deal that could be worth over $1bn.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Includes Equity
    • Co-Promotion
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register